Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug.
McCreary AC, Glennon JC, Ashby CR Jr, Meltzer HY, Li Z, Reinders JH, Hesselink MB, Long SK, Herremans AH, van Stuivenberg H, Feenstra RW, Kruse CG. McCreary AC, et al. Neuropsychopharmacology. 2007 Jan;32(1):78-94. doi: 10.1038/sj.npp.1301098. Epub 2006 May 17. Neuropsychopharmacology. 2007. PMID: 16710314
An in vivo pharmacological evaluation of pardoprunox (SLV308)--a novel combined dopamine D(2)/D(3) receptor partial agonist and 5-HT(1A) receptor agonist with efficacy in experimental models of Parkinson's disease.
Jones CA, Johnston LC, Jackson MJ, Smith LA, van Scharrenburg G, Rose S, Jenner PG, McCreary AC. Jones CA, et al. Among authors: mccreary ac. Eur Neuropsychopharmacol. 2010 Aug;20(8):582-93. doi: 10.1016/j.euroneuro.2010.03.001. Eur Neuropsychopharmacol. 2010. PMID: 20434890
Synthesis, structure-activity relationships, and biological properties of 1-heteroaryl-4-[omega-(1H-indol-3-yl)alkyl]piperazines, novel potential antipsychotics combining potent dopamine D2 receptor antagonism with potent serotonin reuptake inhibition.
Smid P, Coolen HK, Keizer HG, van Hes R, de Moes JP, den Hartog AP, Stork B, Plekkenpol RH, Niemann LC, Stroomer CN, Tulp MT, van Stuivenberg HH, McCreary AC, Hesselink MB, Herremans AH, Kruse CG. Smid P, et al. Among authors: mccreary ac. J Med Chem. 2005 Nov 3;48(22):6855-69. doi: 10.1021/jm050148z. J Med Chem. 2005. PMID: 16250644
Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia.
Rotella DP, McFarlane GR, Greenfield A, Grosanu C, Robichaud AJ, Denny RA, Feenstra RW, Núñez-García S, Reinders JH, Neut Mv, McCreary A, Kruse CG, Sullivan K, Pruthi F, Lai M, Zhang J, Kowal DM, Carrick T, Grauer SM, Navarra RL, Graf R, Brennan J, Marquis KL, Pausch MH. Rotella DP, et al. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5552-5. doi: 10.1016/j.bmcl.2009.08.050. Epub 2009 Aug 15. Bioorg Med Chem Lett. 2009. PMID: 19720528
Piperazinyl oxime ethers as NK-1 receptor antagonists.
van den Hoogenband A, van Maarseveen JH, McCreary AC, Mulder AT, van Scharrenburg GJ, van Stuivenberg HH, Zethof TJ, Zijta B, Iwema Bakker WI. van den Hoogenband A, et al. Among authors: mccreary ac. Bioorg Med Chem Lett. 2006 Feb 15;16(4):1045-8. doi: 10.1016/j.bmcl.2005.10.077. Epub 2005 Nov 11. Bioorg Med Chem Lett. 2006. PMID: 16289817
WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity.
Brennan JA, Graf R, Grauer SM, Navarra RL, Pulicicchio CM, Hughes ZA, Lin Q, Wantuch C, Rosenzweig-Lipson S, Pruthi F, Lai M, Smith D, Goutier W, van de Neut M, Robichaud AJ, Rotella D, Feenstra RW, Kruse C, Broqua P, Beyer CE, McCreary AC, Pausch MH, Marquis KL. Brennan JA, et al. Among authors: mccreary ac. J Pharmacol Exp Ther. 2010 Jan;332(1):190-201. doi: 10.1124/jpet.109.157388. Epub 2009 Oct 14. J Pharmacol Exp Ther. 2010. PMID: 19828876
83 results